Andrew Nicklawsky
Overview
Explore the profile of Andrew Nicklawsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Graham L, Su L, Nicklawsky A, Feng F, Orlicky D, Petraccione J, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002188
The use of supraphysiologic testosterone, particularly when alternated with an anti-androgen agent in men with metastatic castration-resistant prostate cancer (CRPC), has demonstrated promising results in clinical trials. As the use...
2.
Lakritz S, Nicklawsky A, Alami V, Kohli M, Moskaluk C, Riedlinger G, et al.
Clin Genitourin Cancer
. 2025 Jan;
23(1):102293.
PMID: 39793235
Introduction: Alterations in homologous recombination repair (HRR) genes occur in 20%-30% of men with metastatic castration-resistant prostate cancer (mCRPC) which may increase sensitivity to platinum chemotherapy. Specifically, exceptional responses to...
3.
Zimmaro L, Christie A, Altman J, Nicklawsky A, Carson J, Lieu C, et al.
Support Care Cancer
. 2024 Nov;
32(12):830.
PMID: 39604567
Purpose: Colorectal cancer (CRC) significantly impacts patients' physical well-being, often leading to distress and diminished quality of life (QOL). Body compassion (i.e., viewing one's body with kindness, mindfulness, and common...
4.
Goryachok M, Nicklawsky A, Ahmad H, Geiger C, Kim S, Flaig T
JCO Oncol Pract
. 2024 Oct;
:OP2400472.
PMID: 39432865
Purpose: Abiraterone use for prostate cancer can cause mineralocorticoid excess syndrome (MES; eg, hypertension and hypokalemia). Prednisone mitigates these effects; however, the optimal dose level is unclear. This study examines...
5.
Terzian T, Box N, Nicklawsky A, Nern K, Torchia E
Prev Med Rep
. 2024 Sep;
46:102862.
PMID: 39257877
Objectives: To understand whether financial barriers or the lack of accessibility to dermatology services was a significant motivation for the public to seek free skin cancer screening. Methods: An anonymous...
6.
Leach H, Crisafio M, Howell M, Nicklawsky A, Marker R
Transl J Am Coll Sports Med
. 2023 Nov;
8(2).
PMID: 37974897
Introduction/purpose: Virtually supervised, group-based exercise presents an innovative way to expand the reach of exercise-oncology programs and help cancer survivors increase physical activity (PA) and connect with other participants. This...
7.
Vaddi P, Osborne D, Nicklawsky A, Williams N, Ravindran Menon D, Smith D, et al.
Front Immunol
. 2023 May;
14:1173035.
PMID: 37197667
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is an immune checkpoint expressed in regulatory T (Treg) cells and activated T lymphocytes. Despite its potential as a treatment strategy for melanoma, CTLA-4 inhibition...
8.
Walker J, Han D, Nicklawsky A, Boxley P, Morrison J, Tonzi M, et al.
J Urol
. 2023 Feb;
209(6):1186-1193.
PMID: 36821137
Purpose: Although Children's Oncology Group renal tumor protocols mandate lymph node sampling during extirpative surgery for pediatric renal tumors, lymph node sampling is often omitted or low yield. Concerns over...
9.
Han D, Walker J, Nicklawsky A, Boxley P, Halstead N, Tonzi M, et al.
J Urol
. 2023 Feb;
209(3):590.
PMID: 36756967
No abstract available.
10.
Han D, Walker J, Nicklawsky A, Boxley P, Halstead N, Tonzi M, et al.
J Urol
. 2022 Nov;
209(3):582-590.
PMID: 36445021
Purpose: The majority of children with unilateral renal masses suspicious for malignancy undergo radical nephrectomy, while nephron-sparing surgery is reserved for select cases. We investigated the impact of tumor size...